OncoMatch/Clinical Trials/NCT06826768
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
Is NCT06826768 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including REGN5678 and Cemiplimab for prostate cancer.
Treatment: REGN5678 · Cemiplimab — A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: antiandrogen — second-generation
disease progression after at least two lines of systemic therapy, including one line of second-generation anti-androgen therapy
Lab requirements
Blood counts
Hemoglobin ≥8.5 g/dL; ANC ≥1.0 x 10^9/L; Platelet count ≥100 x 10^9/L
Kidney function
Serum creatinine ≤1.5 x ULN or estimated GFR >50 mL/min/1.73 m2
Liver function
Total bilirubin ≤1.5 x ULN (except Gilbert's syndrome); AST ≤2.5 x ULN; ALT ≤2.5 x ULN; ALP ≤2.5 x ULN (≤5 x ULN if tumor liver or bone involvement)
Adequate organ and bone marrow function documented by: Hemoglobin ≥8.5 g/dL; ANC ≥1.0 x 10^9/L; Platelet count ≥100 x 10^9/L. Serum creatinine ≤1.5 x ULN or estimated GFR >50 mL/min/1.73 m2. Adequate hepatic function: Total bilirubin ≤1.5 x ULN; AST ≤2.5 x ULN; ALT ≤2.5 x ULN; ALP ≤2.5 x ULN (≤5 x ULN if tumor liver or bone involvement).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify